DATE & TIME
Thursday, November 12, 2015
6:00 pm - 8:00 pm
King & Spalding
1185 Avenue of the Americas
New York, NY 10036
M&A – What You Need to Know Depends on Which Side You Are On
Mergers and acquisitions (M&A) by large, publicly traded companies are generally covered in the media. But what happens when a small company receives an offer to be acquired or merged into another company? How should the CEO/entrepreneur respond? What information will be required? As a CEO, you envision a stronger, more versatile and profitable company so you begin to seek an acquisition. What do you need to know and what questions should you ask to be sure that this is the right "fit"? What does a successful deal entail?
Our panel of experts will discuss the key "dos and don'ts" for M&A from each perspective. Panelists have extensive experience in leading M&A teams and-or advising entrepreneurs as they navigate the path to M&A success.
This will be an informative and valuable discussion that you should not miss.
Kenneth H. Sonnenfeld, Ph.D., Partner, King & Spalding
Melodie W. Henderson, Patent Attorney, Merck
Matt Jacobson, Partner, King & Spalding
Mark Avagliano, Vice President of Corporate Development, Pfizer
ONLINE, by Nov 9, 2015
LES Member: $25
Future Member: $40
LES Member: $40
Future Member: $55
Online Registration Deadline: Monday, Nov 9, 12 PM EDT
No refunds after Nov 9
Substitutions are permitted
Mark Avagliano is Vice President of Corporate Development at Pfizer, responsible for evaluating, planning and executing large-scale transactions, including acquisitions, joint ventures and divestitures.
Mark joined Pfizer in 2004 from Aventis Pharmaceuticals and has 15 years pharmaceuticals industry experience. Prior to his current role, Mark worked in various transactional, financial and commercial areas, including business development, portfolio and decision analysis, and marketing operations.
Mark earned a master’s degree in Finance and Accounting from the London School of Economics, a master’s degree in Comparative Social Policy from Oxford University, and a bachelor’s degree in Mathematics and Political Science from Marist College.
Melodie W. Henderson is a patent attorney in the Biologics patent group at Merck and is based in Rahway, NJ. She came to Merck via its merger with Schering-Plough. In addition to her legal experience with "big pharma", Melodie has a number of years of legal and scientific experience with small biotechnology companies, including establishing and leading the IP department at Genaissance Pharmaceuticals for almost 6 years.
Melodie has a BS in Biochemistry from University of Kansas - Phi Beta Kappa and Phi Kappa Phi, an MS from St. Louis University and her JD from Connecticut School of Law.
Matt Jacobson is a partner in the firm’s Corporate Practice and resident in the New York and Silicon Valley offices. His practice focuses on a wide variety of corporate, securities and M&A matters for companies ranging from emerging companies to large multinationals. His M&A practice includes significant experience with technology, life sciences and automotive sectors, as well as with cross-border and multi-jurisdictional transactions and corporate divestitures and spin-offs. He has recently handled transactions with significant issues in Brazil, China, France, Germany, India, Italy and the US. Mr. Jacobson also spent five years as corporate counsel for Hewlett-Packard Company, where he was responsible for the acquisition of Compaq (including the proxy contest) and the global integration and restructuring of the companies.
Dr. Sonnenfeld is a partner in the Intellectual Property Group in the New York office of King & Spalding. He has been practicing biotechnology and pharmaceutical patent law for over twenty-five years. His practice focuses on various interparty matters including due diligence, litigation, and licensing. Dr. Sonnenfeld represents both large multinational corporations and startup companies.
Dr. Sonnenfeld has advised companies in a variety of technologies, including small molecule therapeutics, biologics, immunology, vaccines, and neurobiology, among many others. Prior to his career in law, Dr. Sonnenfeld was a research assistant professor at The Mount Sinai School of Medicine in New York.
Dr. Sonnenfeld received a B.A, cum laude, from Kenyon College in The Chemical Basis of Behavior, his M.A., M.Phil and Ph.D. in pharmacology from Columbia University and his J.D. from Fordham University Law School.